WaveMan
WaveMan · Company
SIBN · Si-Bone, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SIBN Si-bone (SIBN) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001459839
Quote by TradingView
Form 144 · 9
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
102
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $332.9K priced

What the filings say about SIBN

Insiders, 180 days
-$5.0M net sold
5 sellers · 26% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$4.4M
9 notices

Si-bone insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, SI-BONE, Inc. insiders sold a net $5.0M of stock across 478 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
FRANCIS LAURA
Chief Executive Officer
SELL
2026-10-14 SECtraded 2026-10-12
38,006
$762.0K
+7.9%
Context
  • 113 earlier Form 4 trades (code P or S) here by this insider (113 sales), the last on Aug 24, 2026.
  • The trade is 10.0% of the 379,256 shares held after it.
  • 3 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer FRANCIS LAURA sold about $762.0K of SIBN under a 10b5-1 plan on Oct 12, 2026; 3 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
Maheshwari Anshul
Chief Op & Financial Officer
SELL
2026-10-06 SECtraded 2026-10-05
1,731
$33.8K
+12.5%
Context
  • 94 earlier Form 4 trades (code P or S) here by this insider (94 sales), the last on Oct 2, 2026.
  • The trade is 0.8% of the 218,235 shares held after it.
  • 3 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Op & Financial Officer Maheshwari Anshul sold about $33.8K of SIBN under a 10b5-1 plan on Oct 5, 2026; 3 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
Maheshwari Anshul
Chief Op & Financial Officer
SELL
2026-10-06 SECtraded 2026-10-02
1,560
$28.3K
+12.5%
Context
  • 92 earlier Form 4 trades (code P or S) here by this insider (92 sales), the last on Aug 21, 2026.
  • The trade is 0.7% of the 221,724 shares held after it.
  • 3 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Op & Financial Officer Maheshwari Anshul sold about $28.3K of SIBN under a 10b5-1 plan on Oct 2, 2026; 3 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
Maheshwari Anshul
Chief Op & Financial Officer
SELL
2026-10-06 SECtraded 2026-10-02
1,758
$32.0K
+12.5%
Context
  • 92 earlier Form 4 trades (code P or S) here by this insider (92 sales), the last on Aug 21, 2026.
  • The trade is 0.8% of the 219,966 shares held after it.
  • 3 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Op & Financial Officer Maheshwari Anshul sold about $32.0K of SIBN under a 10b5-1 plan on Oct 2, 2026; 3 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
PISETSKY MICHAEL A.
SVP, Ops & Adm/Chief Legal Ofr
SELL
2026-10-06 SECtraded 2026-10-02
1,300
$23.7K
+12.5%
Context
  • 30 earlier Form 4 trades (code P or S) here by this insider (30 sales), the last on Aug 17, 2026.
  • The trade is 0.5% of the 272,350 shares held after it.
  • 3 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Ops & Adm/Chief Legal Ofr PISETSKY MICHAEL A. sold about $23.7K of SIBN on Oct 2, 2026; 3 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
478 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 473 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$5.0M over 180 days
-$4.4M over 90 days
below 77% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
102 funds bought in last quarter
more than 64% of Medical Devices
Revenue
+20.2% year over year
more than 72% of Medical Devices
Margin
-9.4% net margin
more than 57% of Medical Devices
Buybacks
no share repurchases reported
Short interest
12.8% of the float short (float per yahoo 2026-10-26) · 8.7 days to cover · settled 2026-09-30
more than 92% of Medical Devices
What changed in the last 30 days
Oct 14Chief Executive Officer FRANCIS LAURA sold $762.0K under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 13Director DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 filed to sell $736.2K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 6Chief Op & Financial Officer Maheshwari Anshul sold $94.1K under a 10b5-1 plan (3 trades, Oct 2 to Oct 5)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6SVP, Ops & Adm/Chief Legal Ofr PISETSKY MICHAEL A. sold $56.9K (Oct 2)
Oct 5Director DUNN JEFFREY W sold $369.4K (Oct 1)

Watch SIBN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+39.5%12M
-25%-3%+18%+40%2025-102025-122026-022026-042026-062026-082026-10 2025-11-11 · DUNN JEFFREY W sold $1.1M2026-08-20 · FRANCIS LAURA sold $1.0M2026-10-12 · FRANCIS LAURA sold $762.0K2026-02-17 · FRANCIS LAURA sold $608.0K2026-08-24 · FRANCIS LAURA sold $522.6K2025-11-11 · DUNN JEFFREY W sold $438.7K2026-01-08 · DUNN JEFFREY W sold $425.6K2025-12-18 · PISETSKY MICHAEL A. sold $394.9K2025-12-18 · Maheshwari Anshul sold $373.6K2026-10-01 · DUNN JEFFREY W sold $369.4K2026-08-03 · DUNN JEFFREY W sold $369.2K2025-12-08 · DUNN JEFFREY W sold $362.6K2026-09-01 · DUNN JEFFREY W sold $352.3K2026-02-17 · FRANCIS LAURA sold $289.4K2026-02-17 · FRANCIS LAURA sold $239.0K2026-08-21 · Maheshwari Anshul sold $224.8K2026-02-17 · PISETSKY MICHAEL A. sold $177.5K2026-02-17 · RECUPERO ANTHONY J sold $171.7K2026-02-17 · Maheshwari Anshul sold $170.6K2026-02-17 · FRANCIS LAURA sold $121.8K2026-08-19 · Maheshwari Anshul sold $112.4K2025-11-18 · FRANCIS LAURA sold $95.8K2025-11-11 · FRANCIS LAURA sold $92.3K2026-08-21 · FRANCIS LAURA sold $78.5K2026-08-17 · FRANCIS LAURA sold $72.6K2026-08-17 · FRANCIS LAURA sold $68.1K2025-11-17 · FRANCIS LAURA sold $67.6K2026-02-17 · Maheshwari Anshul sold $60.0K2026-08-17 · FRANCIS LAURA sold $59.8K2026-02-17 · FRANCIS LAURA sold $59.5K2026-05-18 · FRANCIS LAURA sold $57.4K2026-03-12 · Nishimura Mika sold $56.7K2025-11-17 · FRANCIS LAURA sold $55.7K2026-05-28 · Davis Timothy E JR sold $54.7K2026-06-05 · DUNN JEFFREY W sold $54.5K2026-05-18 · FRANCIS LAURA sold $53.9K2026-02-17 · PISETSKY MICHAEL A. sold $50.8K2026-05-29 · Davis Timothy E JR sold $49.5K2026-02-17 · FRANCIS LAURA sold $49.0K2025-11-11 · Maheshwari Anshul sold $47.7K2026-02-17 · Maheshwari Anshul sold $47.4K2026-02-17 · RECUPERO ANTHONY J sold $47.4K2026-10-13 · DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 filed to sell $736.2K2026-10-05 · ANSHUL MAHESHWARI filed to sell $31.3K2026-08-24 · DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 filed to sell $518.4K2026-08-24 · ANSHUL MAHESHWARI filed to sell $232.3K2026-08-21 · DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 filed to sell $76.4K2026-08-21 · ANSHUL MAHESHWARI filed to sell $218.7K2026-08-20 · DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 filed to sell $1.0M2026-08-19 · ANSHUL MAHESHWARI filed to sell $110.0K2026-08-03 · THE JEFFREY W DUNN LIVING TRUST DTD 05/17/2012 filed to sell $1.4M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SIBN: institutional holders (13F)

13F holdings, latest reported quarter
First Light Asset Management, LLC
8,127,985 sh
$132.6M
BlackRock, Inc.
3,676,259 sh
$60.0M
CADIAN CAPITAL MANAGEMENT, LP
3,347,574 sh
$54.6M
AMERICAN CENTURY COMPANIES INC
2,510,963 sh
$41.0M
BROWN ADVISORY INC
2,077,134 sh
$33.9M

Congress trades in SIBN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SIBN planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003
Filed 2026-10-13
$736.2K
ANSHUL MAHESHWARI
Filed 2026-10-05
$31.3K
DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003
Filed 2026-08-24
$518.4K
ANSHUL MAHESHWARI
Filed 2026-08-24
$232.3K
DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003
Filed 2026-08-21
$76.4K

SIBN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Impax Small Cap Fund
$23.3M position · as of 2026-06-30
2.5%
Harbor Active Small Cap Growth ETF
$524.2K position · as of 2026-07-31
2.0%
Royce Smaller-Companies Growth Fund
$4.3M position · as of 2026-06-30
1.8%
VELA SMALL CAP FUND
$3.1M position · as of 2026-06-30
1.7%
Nuveen Small Cap Growth Opportunities Fund
$3.7M position · as of 2026-07-31
1.4%
Paradigm Micro-Cap Fund
$2.3M position · as of 2026-06-30
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 4
1 active
7
Not applicable
4 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Mr. Dunn
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.5M
$10.0M
$2.5M
-34%
+23%
2024
$7.1M
$2.5M
$2.5M
-53%
+14%
2023
$3.7M
$7.1M
$2.0M
-30%
+5%
2022
$4.9M
$2.6M
$2.2M
-55%
+1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.0M sold by insiders over 180 days, 102 funds added last quarter, $4.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDWRBYISRGTXGDXCMEWTMDXOMIRMDLUNG

SIBN financials

Revenue growth
+20.2%
XBRL, annual
Net margin
-9.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$213.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-6.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$4.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.20x
long-term 2026-06-30 plus current 2022-09-30 (45 months older than the period end); equity 2026-06-30
Cash flow to debt
0.07x
TTM operating cash flow over long-term 2026-06-30 plus current 2022-09-30 (45 months older than the period end)
Return on equity
-8.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-6.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-8.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$966.7M
market value at close 2026-10-23 on 2026-07-29 shares, plus long-term 2026-06-30 plus current 2022-09-30 (45 months older than the period end), minus cash 2026-06-30
FCF yield
-0.5%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$200.9M$167.2M$138.9M$106.4M
Gross profit$159.9M$132.1M$109.4M$90.7M
Operating income-$22.3M-$35.2M-$46.9M-$59.6M
Net income-$18.9M-$30.9M-$43.3M-$61.3M
EPS (diluted)-0.44-0.75-1.13-1.79
Operating cash flow-$675.0K-$12.4M-$18.7M-$41.7M
Cash$42.2M$34.9M$33.3M$20.7M
Long-term debt$35.6M$35.5M$36.1M$35.2M
SEC XBRL, fiscal years, as known on 2026-10-27

SIBN Stock Sonar score 6/7 axes

Find similar shapesCompare

SIBN ranks highest on growth (72nd percentile) and profitability (60th), and lowest on insider conviction (15th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
60
Inputs
  • Return on equity-8.3% · 61 pct, sector of 183
  • Return on assets-6.1% · 62 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-8.2% · 57 pct, sector of 188
Financial health
58
Inputs
  • Debt to equity0.20x · 59 pct, sector of 159
  • Cash flow to debt0.07x · 56 pct, sector of 150
Growth
72
Inputs
  • Revenue growth, YoY+20.2% · 72 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
15
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.8M · 30 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
32
Inputs
  • Funds adding, latest quarter102 · 64 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$20K · 0 pct, sector of 50
Risk and compliance
54
Inputs
  • Short interest, % of float+12.8% · 13 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+10.8% · 49 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SIBN filings, in plain words

Are Si-bone insiders buying or selling SIBN?

In the 180 days to 2026-10-27, Si-bone insiders were net sellers, a net $5.0M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of SIBN?

Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $4.4M of stock; the latest, by DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003, was filed 2026-10-13.

Read the full summary

In the 180 days to 2026-10-27, Si-bone insiders were net sellers of SIBN, a net $5.0M across purchases and sales reported on Form 4 by 5 sellers. 26% of the 43 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $4.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies